Company intelligence / Profile preview

Bencard Allergie

Munich, Bavaria, Germany
Ownership
Private
Employees
~156
Development stage
Other
01

Overview

Bencard Allergie is a leading developer of allergy immunotherapies and adjuvant systems, offering commercialized products for allergy treatment and providing platform technologies for new vaccines and immunotherapies. The company supports both marketed drugs and research into novel adjuvants.

Therapeutic areas
ImmunologyInfectious Diseases
Modalities
BiologicVaccine
Industry
Biotech
02

Drug pipeline

1 asset

alder pollen allergoid

Unknown
03

Partnerships

European Academy of Allergy and Clinical Immunology (EAACI)

Beyond the preview

Go deeper on Bencard Allergie.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bencard Allergie.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call